Hutchmed (China) Limited

Overview

ISIN(s):: KYG4672N1198 (+1 more)
LEI:: 2138006X34YDQ6OBYE79
Country:: Hong Kong
Address:: LEVEL 18, THE METROPOLIS TOWER, KOWLOON
Website:: https://www.hutch-med.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

No description available.

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

Date	Filing	Language	Size
2025-08-26 08:00	Board/Management Information Directorate Change	English	17.9 KB
2025-08-20 08:00	Regulatory News Service HUTCHMED Completes Enrollment of Phase III Trial	English	29.1 KB
2025-08-07 13:00	Earnings Release 2025 Interim Results	English	141.5 KB
2025-07-03 10:30	Report Publication Announcement HUTCHMED to Announce 2025 Half-Year Results	English	12.1 KB
2025-06-30 10:30	Declaration of Voting Results & Voting Rights Announcements Total Voting Rights	English	12.4 KB
2025-06-30 10:30	Remuneration Information Blocklisting Six Monthly Return	English	25.1 KB
2025-06-30 10:30	Regulatory News Service China Approval based on Phase III SACHI Trial	English	29.8 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

No data available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Company	Country	Ticker
2cureX AB Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.	Sweden	2CUREX
4BASEBIO PLC Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.	United Kingdom	4BB
4SC AG Developing small-molecule epigenetic drugs for high-need cancer indications.	Germany	VSC
Abera Bioscience AB Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.	Sweden	ABERA
ABINGDON HEALTH PLC A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.	United Kingdom	ABDX
ABIONYX Pharma Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.	France	ABNX
Abliva Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.	Sweden	ABLI
AB Science Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.	France	AB
Access Bio, Inc. Develops and manufactures rapid diagnostic tests for infectious diseases for global health.	United States of America	950130
Active Biotech Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.	Sweden	ACTI